Frontlight ResearchEarly access
Head and neck cancer trials in Italy
41 of 73 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 18 November 2026. Ask the study team whether a trial fits you.
- Phase 2Taking peopleA Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
- Where
- Bergamo, Genova, Naples, Verona
- Age
- 18 years and over
- People
- 890 worldwide
- Run by
- Daiichi Sankyo
See details and how to joinNCT06172478 · EU 2023-507641-29-00 - No phaseEnrolling by invitationRole of 68Ga-FAPI PET/CT in Patients in Whom 18F-FDG PET/CT Has Been Found to be Questionable or Inconclusive Due to Oncological Pathology
- Where
- Bologna
- Age
- 18 years and over
- People
- 200
- Run by
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
See details and how to joinNCT07942090 - No phaseTaking peopleEffect of Prehabilitation on Head and Neck Cancer Patients
- Where
- Naples, Pavia, Sassari
- Age
- 18 years and over
- People
- 60
- Run by
- Istituti Clinici Scientifici Maugeri SpA
See details and how to joinNCT06593639 - Phase 3Not yet taking people in ItalyLYSARI – LYmphocyte-Sparing And Radio-Immunotherapy in Head and neck carcinoma - A multicenter, randomised 2*2 factorial design comparing standard to reduced-target volume radiotherapy with or without all-trans retinoic acid (ATRA) in patients with lateralised oropharyngeal, laryngeal and hypopharyngeal squamous cell carcinoma.
- Where
- Florence, Rome, Rozzano, Venice
- Age
- 18 years and over
- People
- 630 worldwide
- Run by
- Centre Leon Berard
See details and how to join2022-501315-13-00 - Phase 3Taking peopleA Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer
- Where
- Milan, Naples, Palermo, Pavia, Rome, Rozzano
- Age
- 18 years and over
- People
- 600 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT07276399 · EU 2025-521917-24-00 - Phase 1/2Taking peopleA Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
- Where
- Milan
- Age
- 18 years and over
- People
- 560 worldwide
- Run by
- Genmab
See details and how to joinNCT03526835 · EU 2024-513627-16-01 - Phase 2/3Taking peopleFORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC
- Where
- Bologna, Cagliari, Florence, Lecce, Milan, Naples, Padova, Palermo, Pavia, Pisa, Rome, Rozzano, Siena
- Age
- 18 years and over
- People
- 650 worldwide
- Run by
- Bicara Therapeutics
See details and how to joinNCT06788990 · EU 2024-519654-37-00 - Phase 2Not yet taking people in ItalyDB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
- Where
- Bergamo, Brescia, Ferrara, Florence, Milan, Modena, Pavia, Verona
- Age
- 18 years and over
- People
- 750 worldwide
- Run by
- DualityBio Inc.
See details and how to joinNCT06953089 · EU 2025-523895-22-00 - Phase 2/3Active, not recruitingOrdastobart (INBRX-106) Add-on to Pembrolizumab in 1L HPV+ PD-L1+ R/M OPSCC (HexAgon-HN)
- Where
- Milan, Naples, Pavia
- Age
- 18 years and over
- People
- 450 worldwide
- Run by
- Inhibrx Biosciences, Inc
See details and how to joinNCT06295731 - Phase 1/2Taking peopleA Study to Investigate ALE.P02 as a Monotherapy or in Combination With Pembrolizumab in Adult Patients With Selected CLDN1+ Solid Tumors
- Where
- Milan, Ravenna, Roma, Verona
- Age
- 18 years and over
- People
- 235 worldwide
- Run by
- Alentis Therapeutics AG
See details and how to joinNCT06747585 · EU 2024-515459-39-00 - Phase 1/2Taking peopleA Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
- Where
- Candiolo, Milan, Naples, Rome, Rozzano
- Age
- 18 years and over
- People
- 680 worldwide
- Run by
- Daiichi Sankyo
See details and how to joinNCT06330064 · EU 2023-509632-26-00 - Phase 2Taking peopleA Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
- Where
- Milan, Pieve Emanuele
- Age
- 18 years and over
- People
- 120 worldwide
- Run by
- Regeneron Pharmaceuticals
See details and how to joinNCT06769698 · EU 2024-517620-19-00 - Phase 2Not yet taking people in ItalyA Study Evaluating Ficerafusp Alfa (BCA101) QW in Combination With Pembrolizumab vs Alternative Ficerafusp Alfa Dosing in 1L R or M HNSCC
- Where
- Meldola, Milan, Naples
- Age
- 18 years and over
- People
- 160 worldwide
- Run by
- Bicara Therapeutics
See details and how to joinNCT07807163 · EU 2026-526741-10-00 - Phase 3Not yet taking people in ItalyA Study to Evaluate CRB-701 Compared to Investigator's Choice Therapy in Previously Treated Oropharyngeal Squamous Cell Carcinoma
- Where
- Ancona, Milan, Modena, Pisa, Prato, Rozzano, Verona
- Age
- 18 years and over
- People
- 260 worldwide
- Run by
- Corbus Pharmaceuticals Inc.
See details and how to joinNCT07768189 · EU 2026-527123-94-00 - Phase 1/2Taking peopleThe Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- Where
- Candiolo, Milan, Naples, Rome, Rozzano
- Age
- 12 years and over
- People
- 300 worldwide
- Run by
- PMV Pharmaceuticals, Inc
See details and how to joinNCT04585750 - Phase 1Taking peopleStudy of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
- Where
- Ancona, Bologna, Florence, Milan, Naples, Ravenna
- Age
- 18 years and over
- People
- 1,394 worldwide
- Run by
- Exelixis
See details and how to joinNCT05176483 · EU 2023-510061-10-00 - Phase 3Taking peopleA Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy
- Where
- Aviano, Florence, Milan, Modena, Naples, Padova, Pavia, Rozzano
- Age
- 18 years to 130 years
- People
- 1,145 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06129864 - Phase 1Taking peopleEvaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
- Where
- Candiolo, Rozzano
- Age
- 18 years and over
- People
- 540 worldwide
- Run by
- SystImmune Inc.
See details and how to joinNCT05983432 - Phase 2Taking peopleStudy of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors
- Where
- Alexandria, Bergamo, Orbassano
- Age
- 18 years to 64 years
- People
- 257 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06535607 · EU 2025-523947-36-00 - Phase 1/2Taking peopleA Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
- Where
- Candiolo, Milan, Naples, Roma, Rozzano, Siena
- Age
- 18 years and over
- People
- 1,109 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT04895709 - Phase 1Taking peopleA Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
- Where
- Bologna, Milan, Verona
- Age
- 18 years and over
- People
- 714 worldwide
- Run by
- Seagen, a wholly owned subsidiary of Pfizer
See details and how to joinNCT05208762 · EU 2023-506604-18-00 - No phaseTaking peopleBrief Clinical Psychological Intervention With Biofeedback in Head and Neck Cancer
- Where
- Turin
- Age
- 18 years and over
- People
- 58
- Run by
- University of Turin, Italy
See details and how to joinNCT07712120 - Phase 1/2Taking peopleFirst-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
- Where
- Alexandria, Brescia, Milan, Monza, Pisa, Ravenna, Rome, Verona
- Age
- 18 years and over
- People
- 880 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT05768139 · EU 2023-504807-94-00 - Phase 2Not yet taking people in ItalyPhase 2, open-label, multicentre, single-arm study to evaluate the activity of the combination of EGFR inhibitors and c-MET inhibitors in patients with platinum-resistant head and neck squamous cell carcinoma after relapse to immunotherapy.
- Where
- Bologna, Brescia, Florence, Genoa, Milan, Milano, Padova, Pavia, Rome
- Age
- 18 years and over
- People
- 30
- Run by
- Azienda Socio Sanitaria Territoriale Degli Spedali Civili Di Brescia
See details and how to join2024-518892-72-00 - Phase 3Taking peoplePembrolizumab and Radiotherapy for Oligometastatic Head and Neck Cancer
- Where
- Bologna, Cuneo, Florence, Milan, Naples, Ravenna, Rome, Rozzano
- Age
- 18 years and over
- People
- 200 worldwide
- Run by
- European Organisation for Research and Treatment of Cancer - EORTC
See details and how to joinNCT05815927 · EU 2023-504478-39-00